Skip to main navigation Skip to search Skip to main content

Big business: The private sector market for image and performance enhancing drug harm reduction in the UK

Luke Turnock, Nick Gibbs*, Luke Cox, Timothy Piatkowski

*Corresponding author for this work

    Research output: Contribution to journalArticlepeer-review

    41 Citations (Scopus)
    42 Downloads (Pure)

    Abstract

    This article draws on three mutually independent ethnographic studies to explore the private sector market for image and performance enhancing drug (IPED) harm reduction in the UK, specifically examining (1) steroid accessory supplements; (2) blood testing services; and (3) bloodletting services. After contextualising the work with a discussion of IPED use and harm reduction and the substantial growth of the global health and fitness industry, each private sector provision is critically interrogated with the following questions in mind: what is the role and utility of these services compared to public sector provision? Why has the private sector begun to deliver IPED harm reduction products and services in the UK? And how does this provision relate to the health and fitness industry more broadly? The paper concludes with some reflections about the future direction of IPED harm reduction, the importance of community-led services, and the need to think innovatively if we are to best protect users’ health and wellbeing.
    Original languageEnglish
    Article number104254
    Number of pages13
    JournalInternational Journal of Drug Policy
    Volume122
    Early online date9 Nov 2023
    DOIs
    Publication statusPublished - 1 Dec 2023

    Keywords

    • Image and performance enhancing drugs
    • Harm reduction
    • Steroid accessory supplements
    • Blood testing services
    • Bloodletting services

    Fingerprint

    Dive into the research topics of 'Big business: The private sector market for image and performance enhancing drug harm reduction in the UK'. Together they form a unique fingerprint.

    Cite this